## at 8%. Philip Hammarskjold, the executive chairman at Hellman &

Friedman, notes, “This innovative growth model is a new tool we can

use to drive equity value in our companies by accelerating much needed

patient-care innovation on a cost-eﬀective basis. Looking forward, we

are excited to deploy this model alongside more-traditional growth